Viraha (Sildenafil Citrate) is commonly used to manage two distinct conditions characterized by symptoms linked to organ-specific functional stress: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

---

Supporting Functional Erection for Sexual Health

Viraha is commonly used to help with ED, which is the difficulty in achieving or sustaining a rigid penile erection. It is applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to physical discomfort. The medication supports the body's natural processes for erection, which can support the patient during difficult episodes by easing distress.

“The drug is commonly used to help with maintaining functional stability in this physical domain.”

Management of Pulmonary Arterial Hypertension (PAH)

Viraha is also commonly used to help with symptoms associated with PAH, a condition marked by increased physiological stress due to high blood pressure in the lung arteries. It is applied in addressing symptom clusters that create noticeable physiological strain, particularly shortness of breath and fatigue that interfere with daily functioning. The medication provides supportive relief when symptoms interfere with routine activities, which can support the patient during difficult episodes.

Quick Fact: Support for Symptomatic Functional Strain Viraha is commonly used across conditions presenting with episodic or recurrent manifestations, which may include difficulty maintaining an erection or physical limitations related to high pulmonary pressure.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Viraha — official regulatory information

Populations for whom use is allowed (as stated in label):

• Adult Men for the Erectile Dysfunction (ED) indication.
• Adult Male and Female Patients for the Pulmonary Arterial Hypertension (PAH) indication.
• Pediatric Patients (1 to 17 years old) for the PAH indication.

Populations for whom use is contraindicated (Absolute Ban):

• Patients with concomitant use of organic nitrates or nitric oxide donors (e.g., amyl nitrite), or riociguat (a guanylate cyclase stimulator).
• Patients with severe hepatic impairment (Child-Pugh Class C), a recent history of stroke or myocardial infarction (MI), or severe hypotension (BP <90/50 mmHg).
• Patients with a known hypersensitivity to Sildenafil or any component of the formulation.
• Individuals with vision loss due to Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) in one eye, or certain hereditary degenerative retinal disorders.

Age-related eligibility rules:

• Adults are the approved age group for both ED and PAH indications.
• Not Indicated for individuals under 18 years of age for the ED indication.
• Geriatric Patients (ge 65 years) may require cautious dose consideration due to potential reduced clearance.

Condition-specific eligibility rules:

• Use requires caution in patients with severe renal impairment ( CLcr < 30 mL/min) or mild to moderate hepatic impairment.
• Use is not recommended for patients with Pulmonary Veno-Occlusive Disease (PVOD).

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define strict, non-negotiable prohibitions for specific populations, particularly those taking nitrates or with severe cardiovascular/organ conditions, where the drug presents a documented high risk. For other populations, such as those with organ impairment or anatomical concerns, the label outlines conditions or cautions, classifying them as groups with restricted or conditional eligibility. The allowed population is strictly defined by the approved age group and sex specific to the authorized indication (ED or PAH).

Viraha's potential for interaction with other products is a critical safety consideration, primarily due to its effect on the nitric oxide/cGMP pathway and its metabolism by the CYP3A4 enzyme system.

Contraindicated Combinations

Interacting Product Category	Example Medicines	Interaction Rationale
Nitrates (in any form)	Nitroglycerin, Isosorbide Dinitrate	Potentiation of severe hypotensive effects
GC Stimulators	Riociguat	Risk of profound hypotension

Interactions Requiring Dose Adjustment or Caution

Viraha is metabolized mainly by the liver enzyme CYP3A4. Strong inhibitors of this enzyme increase Viraha levels in the blood, which may necessitate a lower starting dose or a reduction in the maximum frequency of use.

Interacting Product Category	Example Medicines	Action Required
Strong CYP3A4 Inhibitors	Ritonavir, Ketoconazole, Erythromycin	Dose reduction or spacing required. For ritonavir, the maximum dose is limited to 25 mg within 48 hours.
Alpha-blockers / Anti-hypertensives	Tamsulosin, Amlodipine	Use with caution due to risk of additive blood pressure lowering, potentially leading to symptomatic hypotension. Viraha should be started at the lowest dose (25 mg) in patients already stable on alpha-blocker therapy.

Patients should avoid using other PDE5 inhibitors, and be aware that grapefruit products may also increase Viraha plasma concentrations.

How Viraha Works — Mechanism of Action

Viraha operates as a selective competitive inhibitor of the enzyme Phosphodiesterase type 5 ( PDE5), which is predominantly located in the vascular smooth muscle cells of the corpus cavernosum and pulmonary arteries. This interaction prevents PDE5 from hydrolyzing the second messenger cyclic Guanosine Monophosphate ( cGMP).

The drug's action sustains the effect of the natural NO/cGMP signaling cascade. The resulting accumulation of cGMP inside the cell activates Protein Kinase G ( PKG), leading to the deactivation of the smooth muscle contractile apparatus. This cascade mediates the relaxation of vascular smooth muscle cells (vasodilation) in the targeted tissue, which is the direct system-level physiological consequence of the drug's mechanism.

This vasodilation results in increased localized tissue perfusion and blood flow within the specific vascular beds where PDE5 is expressed.

How to Use Viraha: Official Administration Guidelines

Viraha (Sildenafil Citrate) usage is governed by two separate protocols, determined by the approved therapeutic indication. The medicine is officially administered via the oral route (tablet or suspension) or by intravenous (IV) bolus injection.

---

Dosing Patterns and Frequency

For Erectile Dysfunction (ED), administration follows an as-needed schedule, with a maximum frequency of once per day. The typical starting oral dose is 50 mg, which may be adjusted within a range of 25 mg to a maximum of 100 mg. The dose is generally taken between 30 minutes and 4 hours prior to activity, but a high-fat meal may delay the onset of its activity.

For Pulmonary Arterial Hypertension (PAH), the use pattern is a fixed, three-times daily (TID) scheduled regimen. The typical oral dose is 20 mg TID, which may be titrated up to a maximum of 80 mg TID. The intravenous dose is fixed at 10 mg TID and is reserved for patients temporarily unable to tolerate the oral forms.

Administration Conditions and Adjustments

The oral suspension form requires reconstitution with water and must be measured using a calibrated device. Dosing adjustments are also officially defined for specific patient populations: a lower starting oral dose of 25 mg is typically considered for the ED regimen in older adults (ge 65 years) and patients with severe hepatic or renal impairment.

Research Evidence: Overview of Studies for Viraha (Sildenafil Citrate)

The research base for Viraha primarily comes from randomized, double-blind, placebo-controlled trials—the highest standard of clinical study—and subsequent long-term follow-up studies. These studies were studied for the medicine's use in the two main conditions it addresses: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

---

Evidence for use in Erectile Dysfunction (ED)

The core research examining Viraha for ED involves numerous large-scale, short-term placebo-controlled trials. These studies monitored outcomes related to physical discomfort and functional balance by asking participants to log events and complete validated questionnaires on sexual function, specifically examining the ability to achieve and maintain an erection.

The findings describe patterns observed in the studies where participants receiving the medicine reported measured scores that were statistically different than those receiving an inactive placebo. Subgroup analysis explored whether results applied in studies examining patient-reported experiences to men with complicating factors like diabetes or those who had undergone radical prostatectomy. While studies reported overall patterns of change, the extent of the differences measured was observed in some studies to be smaller in these more complex patient groups.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

For PAH, which is a condition marked by functional limitations, evidence primarily comes from pivotal controlled trials that were typically short-term. These studies evaluated outcomes reflecting daily functioning, such as the 6-Minute Walk Distance (6MWD). Research reports indicate differences in the measured 6MWD compared to placebo. Additionally, studies explored changes in physiological measurements and disease progression, where some reports suggest that the time to clinical worsening was observed to be longer compared to the placebo group.

---

Long-Term Studies and Follow-Up Data

To contribute to the broader evidence landscape, many of the initial controlled trials were followed by open-label extension studies. These allow researchers to observe participants for longer periods, often several years, to gather information about the persistence of reported outcomes.

For both ED and PAH, the body of evidence remains limited for long-term outcomes from large-scale, placebo-controlled trials. Therefore, certainty remains low for long-term outcomes when compared to the initial findings from short-term controlled trials.

Evidence in Special and Comorbid Populations

A key distinction exists for pediatric patients (children) with PAH. Specialized trials were studied for this population. While the initial short-term findings suggested some measured outcomes, a long-term extension study later suggested an association with increased mortality risk when higher dosage levels were observed. This finding prompted regulatory review regarding observed outcomes in studies involving long-term exposure in children for PAH.

Major Evidence Gaps and Areas of Uncertainty

A primary gap is the lack of extensive, multi-year Randomized Controlled Trials for both indications, meaning the body of evidence remains limited for long-term outcomes. Additionally, comparative evidence is lacking for many direct comparisons between Viraha and other similar medications in the same class. Subgroup findings are uncertain or suggest a more modest pattern of change compared to the general trial population, meaning results apply only to the populations studied and cannot be assumed to apply universally.

Key Studies & References

1. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction

Common questions about Viraha (FAQ)

Q: How long do the effects of Viraha (ED dose) last?

Official product information for Viraha states that the active substance, Sildenafil, has a terminal half-life of approximately 3 to 5 hours. Clinical trials indicated that the drug was still able to facilitate an erection in response to stimulation for up to 4–5 hours following the dose.

---

Q: How much water is needed to mix the oral suspension?

Regulatory documents for the powdered form of Viraha state that the oral suspension must be carefully reconstituted with a specific, measured volume of water. The preparation instructions specify a final volume of 90 mL of reconstituted suspension. The measuring device must be calibrated for proper use.

---

Q: Can women use Viraha, and if so, for what condition?

Official information indicates that Viraha (Sildenafil) is approved for use in adult women for the treatment of Pulmonary Arterial Hypertension (PAH). The medication is specifically not indicated or approved for use by women for the Erectile Dysfunction indication.

---

Q: What temperature is too hot for storing the tablets?

The official product labeling requires Viraha tablets to be stored at a controlled room temperature, typically between 20 C and 25 C (68 F to 77 F). Regulatory guidelines indicate that the product should not be stored above 30 C to help maintain its quality.

---

Q: How quickly does the IV bolus injection for PAH start working?

The intravenous (IV) injection is intended for patients temporarily unable to take the oral form of the medicine. The IV route bypasses the initial absorption process in the stomach, allowing the active ingredient to be delivered directly into the bloodstream for systemic exposure.

---

Q: Is there a generic version of Viraha available?

Official regulatory databases, such as the FDA’s Approved Drug Products list, confirm that generic versions of the active ingredient, Sildenafil Citrate, are approved. These versions are widely available once the original patent expires.

---

Q: How should a patient switch from the oral form to the IV form for PAH?

Regulatory dosing guidance indicates that the intravenous injection is reserved for patients temporarily unable to take the medicine by mouth. Official documents note that the 10 mg intravenous dose is predicted to provide a pharmacological effect equivalent to the standard 20 mg oral dose.

---

Q: What is the exact chemical structure of Sildenafil Citrate?

Official regulatory documents identify the exact chemical structure of Sildenafil Citrate, the active substance in Viraha. This includes its complete chemical name and formula, which are used to precisely define the composition of the medicine.

---

Q: If I miss a scheduled PAH dose, what should I do?

Official patient information generally advises that if a scheduled dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next dose, the missed dose should be skipped entirely. Instructions caution against taking two doses together to compensate for a missed dose.

The official regulatory requirements for storing and disposing of sildenafil (Viraha) tablets focus on maintaining product stability and ensuring safety.

Storage and Handling

Requirement Type	Official Labeled Mandate
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C (EMA).
Protection	Keep the product in the original container and ensure the container is tightly closed to protect it from moisture.
Child Safety	Keep the medication out of the sight and reach of children.
Stability	Stability is defined by the package expiration date; for the oral suspension form, the product must be discarded 60 days after reconstitution.

Disposal Instructions

To dispose of unused or expired tablets, follow the official FDA-recommended procedure: use a drug take-back program. If a take-back option is unavailable, the drug must be disposed of in the household trash. This involves removing the medicine from its original container, mixing it with an undesirable substance (such as dirt or used coffee grounds), and placing the mixture in a sealed bag before trashing. Sildenafil is not on the official FDA flush list and should not be flushed down a toilet or poured down a sink.